ArticleJournal of molecular histology2026
Electroacupuncture confers neuroprotection against ischemic stroke via the DNA methylation-RhoGDIα axis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Electroacupuncture (EA) has emerged as a promising alternative therapy for ischemic brain injury, yet its underlying molecular mechanisms remain incompletely understood. This study investigated the neuroprotective effects and epigenetic mechanisms of EA in a mouse model of ischemic stroke. Cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) in mice. EA was applied at Baihui (GV20) and left Zusanli (ST36) acupoints following surgery. Neurological deficits were assessed, infarct volume was measured by TTC staining, and neuronal damage was evaluated by Nissl staining. RhoGDIα protein expression was determined by Western blot. Global DNA methylation was quantified by ELISA, and promoter-specific methylation of RhoGDIα was examined by quantitative methylation-specific PCR (MSP), and mRNA expression of candidate DNA methyltransferases (DNMTs) and demethylases (TETs) was measured by qPCR. EA alleviated MCAO-induced brain injury, as reflected by improved neurological scores, reduced infarct volume, and attenuated neuronal loss. RhoGDIα expression was downregulated after MCAO and restored by EA treatment. Pharmacological inhibition of RhoGDIα abolished the neuroprotective effects of EA, underscoring its essential role in EA-mediated protection. Mechanistically, MCAO induced hypermethylation of the RhoGDIα promoter, which was reversed by EA, leading to restoration of RhoGDIα expression. Furthermore, co-administration of the DNA methylation inhibitor 5-Azacytidine synergistically enhanced the neuroprotective efficacy of EA. Our findings demonstrate that EA ameliorates ischemic brain injury in association with epigenetic regulation of RhoGDIα via promoter demethylation. This study identifies RhoGDIα as a key mediator of EA-induced neuroprotection and suggests that the DNA methylation-RhoGDIα axis may represent a promising therapeutic target for ischemic stroke.
Indexed as
Identifiers
42525157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.